PITTSBURGH--(BUSINESS WIRE)--Helomics Corporation, a privately-held comprehensive personalized healthcare company that develops proprietary innovative next generation diagnostics for the oncology field, announced today that the Company is scheduled to present at the Personalized Medicine World Conference taking place in Mountain View, CA on January 26-28, 2015.
Neil Campbell, President and Chief Executive Officer of Helomics, will provide an overview of the personalized healthcare landscape, the Company’s business and it’s comprehensive tumor profiling technologies during his live presentation and will be available to participate in one-on-one meetings.
Event: |
Personalized Medicine World Conference |
||||||||
Date: |
Tuesday, January 27, 2015 | ||||||||
Time: |
11:30am (Pacific Time), Track 3 | ||||||||
Location: |
Computer History Museum, Mountain View, CA | ||||||||
About Personalized Medicine World Congress
The Personalized
Medicine World Conference (PMWC) is an independent and established
conference that attracts globally recognized authorities and experts
across healthcare and biotechnology sectors. The Conference showcases
practical content and disease pathways that help close the knowledge gap
between different sectors, thereby catalyzing cross-functional
collaboration to further adoption of personalized medicine in the
clinic. For more information please visit: http://pmwcintl.com/index.php.
About Helomics™ Corporation
Helomics is a comprehensive
personalized healthcare company, bringing the next generation of
diagnostics to the oncology field. Helomics is dedicated to improving
patient outcomes by providing a comprehensive personalized tumor profile
utilizing a proprietary set of laboratory platforms that leverage both
live and fixed cellular analysis to allow physicians to personally
characterize malignant tumors. Helomics’ novel molecular and cellular
markers and bioinformatics services are designed to support treatment
decisions by providing vital information based on the specific
biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.